Trial Profile
10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Feb 2022
Price :
$35
*
At a glance
- Drugs Decitabine (Primary) ; Antithymocyte globulin; Fludarabine
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 06 Apr 2021 Results assessing safety and efficacy of 10-day decitabine, fludarabine and 2 Gray TBI prior to allogeneic hematopoietic cell transplantation in poor risk acute myeloid leukemia patients, published in the Bone Marrow Transplantation.
- 18 Mar 2020 Status changed from active, no longer recruiting to completed.
- 03 May 2019 Planned primary completion date changed from 1 Apr 2019 to 1 Oct 2019.